BioGend Therapeutics Past Earnings Performance
Past criteria checks 0/6
BioGend Therapeutics's earnings have been declining at an average annual rate of -0.8%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 80.3% per year.
Key information
-0.8%
Earnings growth rate
11.2%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 80.3% |
| Return on equity | -16.8% |
| Net Margin | -142.2% |
| Next Earnings Update | 09 May 2024 |
Revenue & Expenses BreakdownBeta
How BioGend Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 110 | -156 | 95 | 171 |
| 30 Sep 23 | 81 | -177 | 91 | 170 |
| 30 Jun 23 | 70 | -187 | 85 | 178 |
| 31 Mar 23 | 37 | -191 | 80 | 171 |
| 31 Dec 22 | 31 | -184 | 76 | 166 |
| 30 Sep 22 | 25 | -145 | 70 | 155 |
| 30 Jun 22 | 18 | -132 | 66 | 124 |
| 31 Mar 22 | 13 | -136 | 57 | 122 |
| 31 Dec 21 | 9 | -138 | 54 | 113 |
| 30 Sep 21 | 5 | -156 | 48 | 98 |
| 30 Jun 21 | 3 | -161 | 45 | 106 |
| 31 Mar 21 | 2 | -155 | 43 | 102 |
| 31 Dec 20 | 1 | -146 | 40 | 94 |
| 30 Sep 20 | 1 | -163 | 40 | 112 |
| 30 Jun 20 | 1 | -159 | 38 | 117 |
| 31 Mar 20 | 1 | -163 | 37 | 126 |
| 31 Dec 19 | 1 | -163 | 35 | 133 |
| 30 Sep 19 | 1 | -159 | 34 | 131 |
| 30 Jun 19 | 1 | -164 | 35 | 130 |
| 31 Mar 19 | 0 | -166 | 35 | 131 |
| 31 Dec 18 | 0 | -167 | 34 | 132 |
| 31 Dec 17 | 0 | -130 | 10 | 134 |
Quality Earnings: 6733 is currently unprofitable.
Growing Profit Margin: 6733 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6733 is unprofitable, and losses have increased over the past 5 years at a rate of 0.8% per year.
Accelerating Growth: Unable to compare 6733's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6733 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.1%).
Return on Equity
High ROE: 6733 has a negative Return on Equity (-16.82%), as it is currently unprofitable.